Document


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act 1934
 
Date of Report (date of earliest event reported): September 5, 2017
 
MIMEDX GROUP, INC.
(Exact name of registrant as specified in charter)
 
Florida
(State or other jurisdiction of incorporation)
 
001-35887
(Commission File Number)
 
26-2792552
(IRS Employer Identification No.)
 
1775 West Oak Commons Ct, NE
Marietta, GA
(Address of principal executive offices)
 
30062
(Zip Code)
 
(770) 651-9100
(Registrant’s telephone number, including area code)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o    
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.     o




Item 2.02     Results of Operations and Financial Condition
Item 8.01    Regulation FD Disclosure

On September 5, 2017, MiMedx issued a press release announcing its expectations for revenues for the period ended September 30, 2017. A copy of the press release is furnished as Exhibit 99.1 and incorporated herein by reference.

Item 9.01    Financial Statements and Exhibits

(d)    Exhibits

99.1    MiMedx Group, Inc. press release dated September 5, 2017.


 SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated:
September 5, 2017
MIMEDX GROUP, INC.
 
 
 
 
 
 
 
 
 
 
 
By:
/s/: Michael J. Senken
 
 
 
 
Michael J. Senken, Chief Financial Officer